Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

Article  PubMed  Google Scholar 

The American Cancer society medical and editorial content team. Survival Rates for Ovarian Cancer. Americal cancer Society. Last Revised: Mar 1, 2023 [cited 2023 Aug 3]. Available from: https://www.cancer.org/cancer/types/ovarian-cancer/detection-diagnosis-staging/survival-rates.html

The American Cancer society medical and editorial content team. Survival Rates for Endometrial Cancer. Americal cancer Society. Last Revised: Mar 1, 2023 [cited 2023 Aug 3]. Available from: https://www.cancer.org/cancer/types/endometrial-cancer/detection-diagnosis-staging/survival-rates.html

The American Cancer society medical and editorial content team. Survival Rates for Endometrial Cancer. Americal cancer Society. Last Revised: Mar 1, 2023 [cited 2023 Aug 3]. Available from: https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/survival.html

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505. https://doi.org/10.1056/NEJMoa1810858.

Article  CAS  PubMed  Google Scholar 

González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962.

Article  PubMed  Google Scholar 

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28. https://doi.org/10.1056/NEJMoa1911361.

Article  CAS  PubMed  Google Scholar 

Olivier T, Prasad V. PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings. J Cancer Res Clin Oncol. 2023;10:1–4. https://doi.org/10.1007/s00432-023-04748-5.

Article  CAS  Google Scholar 

Sharon Worcester. Increased Risk for Death Prompts Withdrawal of Three PARPi Indications for Ovarian Cancer. Medscape. 2022 Sep 23 [cited 2023 Aug 3]. Available from: https://www.medscape.com/viewarticle/981369

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. https://doi.org/10.1056/NEJMoa052985. (PMID: 16394300).

Article  CAS  PubMed  Google Scholar 

Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY, Seo SS, Kang S, Yun JY, Cho DS. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374–83.

Article  PubMed  PubMed Central  Google Scholar 

Aronson L, Lopez-Yurda MI, Koole SN, Schagen van Leeuwen JH, Schreuder H, Hermans R, de Hingh IH, Van Gent MD, Arts HJ, van Ham M, Van Dam P. Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.

Classe JM, Meeus P, Leblanc E, Wernert R, Quenet F, Marchal F, Houvenaeghel G, Bats AS, Ferron G, Brigand C, Berton D. Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: the CHIPOR randomized phase III trial. https://doi.org/10.1200/JCO.2023.41.16_suppl.5510.

Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, De Hingh IH, Van Der Velden J, Arts HJ, Massuger LF, Aalbers AG. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New Engl J Med. 2018;378(3):230–40. https://doi.org/10.1056/NEJMoa1708618. (PMID: 29342393).

Article  PubMed  Google Scholar 

Margioula-Siarkou C, Almperis A, Papanikolaou A, Laganà AS, Mavromatidis G, Guyon F, Dinas K, Petousis S. HIPEC for gynaecological malignancies: a last update. Med Int. 2023;3(3):1–9. https://doi.org/10.3892/mi.2023.85. (PMID:37205988;PMCID:PMC10189421).

Article  Google Scholar 

DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609. https://doi.org/10.1200/JCO.22.01549. (10.1056/NEJMoa1911361. PMID: 31851799).

Article  CAS  PubMed  Google Scholar 

Banerjee S, Imbimbo M, Roxburgh P, Kim JW, Kim MH, Plummer R, Stemmer S, You B, Ferguson M, Penson RT, O'Malley D. Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer.

Harter P, Trillsch F, Okamoto A, Reuss A, Kim JW, Rubio-Pérez MJ, Vardar MA, Scambia G, Tredan O, Nyvang GB, Colombo N. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther. 2021;21(7):945–62. https://doi.org/10.1080/14712598.2021.1936494. (Epub 2021 Jun 15. PMID: 34043927).

Article  CAS  PubMed  Google Scholar 

Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol. 2023;41(13):2436.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moore KN, Angelergues A, Konecny GE, Banerjee SN, Pignata S, Colombo N, Moroney JW, Cosgrove C, Lee JY, Roszak A, Breuer S. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147(2):402–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, Ricci C, Scambia G, Fagotti A. Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments. InSeminars in Cancer Biology 2021 Dec 1 (Vol. 77, pp. 144–166). Academic Press. doi: https://doi.org/10.1016/j.semcancer.2021.08.011. Epub 2021 Aug 28. PMID: 34464704].

Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108(3):619–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, Grandits M, López-Abente J, Palhares LC, Chan Wah Hak C, Robinson A. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342–53. https://doi.org/10.1038/s41416-022-02031-x. (PMID: 36402875; PMCID: PMC9902484).

Article  CAS  PubMed  Google Scholar 

Birrer MJ, Betella I, Martin LP, Moore KN. Is targeting the folate receptor in ovarian cancer coming of age? Oncologist. 2019;24(4):425–9. https://doi.org/10.1634/theoncologist.2018-0459. (PMID: 30635448; PMCID: PMC6459241).

Article  PubMed  PubMed Central  Google Scholar 

Corner C, Talk TV. Roche receives FDA approval for VENTANA FOLR1 (FOLR1–2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE.

Richardson DL, Harter P, O'Malley DM, Gonzalez Martin A, Herzog TJ, Rogalski C, Lemming R, Keeton E, Burger RA, Mirza MR. UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): a study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.

O’Malley DM, Myers TK, Zamagni C, Diver E, Lorusso D. GLORIOSA: a randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau G, Long BJ, Marsh RL, Seward SM. ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)

Barroilhet LM, Lim MC, Gupta S, Jada SR, LEE JY, Gilbert L, Edraki B, Cosgrove C, Barlin JN, Provencher DM, Rob L. FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.

Zhang X, Zeng Q, Cai W, Ruan W. Trends of cervical cancer at global, regional, and national level: data from the Global Burden of Disease study 2019. BMC Public Health. 2021;21(1):1.

Google Scholar 

Lei J, Ploner A, Elfström KM, Wang J, Roth A, Fang F, Sundström K, Dillner J, Sparén P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–8. https://doi.org/10.1056/NEJMoa1917338. (PMID: 32997908).

Article  CAS  PubMed  Google Scholar 

Torjesen I. HPV vaccine cut cervical cancer rates in England by 87%. https://doi.org/10.1136/bmj.n2689 (Published 05 November 2021).

National cancer Institute. Cervical Cancer Prognosis and Survival Rates. Updated: Apr 27, 2023 [citied 2023 Aug 3]. Available from: https://www.cancer.gov/types/cervical/survival

Jing H, Xiuhong W, Ying Y, Xiyun C, Deping L, Changmei S, Qi W, Tao P, Yiyun P. Complications of radical hysterectomy with pelvic lymph node dissection for cervical cancer: a 10-year single-centre clinical observational study. BMC Cancer. 2022;22(1):1–9. https://doi.org/10.1186/s12885-022-10395-9.

Article  CAS  Google Scholar 

Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Marth C, Tamussino K. An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): a Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX. 5-SHAPE).

Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gumus M, Olivera Hurtado de Mendoza M. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab+ chemotherapy vs placebo+ chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. https://doi.org/10.1200/JCO.2023.41.16_suppl.5500.

Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609–19.

Article  CAS  PubMed  Google Scholar 

Bogani G, Coleman RL, Vergote I, Raspagliesi F, Lorusso D, Monk BJ. Tisotumab vedotin in recurrent or metastatic cervical cancer. Curr Probl Cancer. 2023;10: 100952.

Article  Google Scholar 

Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol. 2021;14:1–20. https://doi.org/10.1186/s13045-021-01053-x.

Article  CAS  Google Scholar 

Chen J, Li K, Hu Y, Han Y, Shen Y, Wang Y, Song K, Xia B, Chen X, Zou D, Wang Y. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): a prospective, single-arm, phase II trial.

Ray-Coquard IL, Kaminsky-Forrett MC, Ohkuma R, De Montfort A, Joly F, Treilleux I, Ghamry-Barrin S, Bello-Roufai D, Saintigny P, Angelergues A, Michon L. In situ immune impact of nivolumab+ ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

Reijntjes B, van Suijlichem M, Woolderink JM, Bongers MY, Reesink-Peters N, Paulsen L, van der Hurk PJ, Kraayenbrink AA, Apperloo MJ, Slangen B, Schukken T. Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: long-term outcomes of a randomised trial. Gynecol Oncol. 2022;164(2):265–70.

Article  PubMed  Google Scholar 

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–28.

Article  PubMed  Google Scholar 

Lu KH, Broaddus RR. Endometrial cancer. N Engl J Med. 2020;383(21):2053–64.

Article  CAS  PubMed  Google Scholar 

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–13. https://doi.org/10.1002/cncr.30496. (Epub 2017 Jan 6 PMID: 28061006).

Article  CAS  PubMed  Google Scholar